Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference | ||
By: GlobeNewswire - 29 Mar 2023 | Back to overview list |
|
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a virtual fireside chat during the Guggenheim Genomic Medicines and Rare Disease Conference on Tuesday, April 4, 2023 at 9:00 a.m. Eastern Time. A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event. About Entrada Therapeutics For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn. Investor and Media Contact |
||
|
||
Copyright 2023 GlobeNewswire | Back to overview list |